Amgen, Kyowa Hakko Kogyo Ltd. deal

Kyowa Hakko granted Amgen exclusive rights to develop and commercialize KW-0761 for all non-cancer indications outside of Japan, Korea, China and Taiwan, where Kyowa Hakko retains rights. KW-0761 is ...